CheckMate 025
CheckMate 025 was the trial that brought immunotherapy to kidney cancer: nivolumab helped people live longer than everolimus after anti-angiogenic drugs had failed, with fewer side effects.
Overview
CheckMate 025 randomised 821 patients with advanced clear cell renal cell carcinoma who had received one or two prior anti-angiogenic regimens to nivolumab or to everolimus, then the standard second-line drug. The primary endpoint was overall survival.
Nivolumab lengthened overall survival and produced more objective responses than everolimus, regardless of PD-L1 expression, with fewer grade 3 to 4 adverse events and better quality of life. It was approved in the United States in November 2015, the first checkpoint inhibitor in kidney cancer, and the combinations of nivolumab with ipilimumab or cabozantinib that followed (CheckMate 214 and 9ER) moved immunotherapy into first line.
Similar pages
not linked directly; found by shared links- TrialCARMENA
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag subtype-trials.
- TrialA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance
Shares Clear cell renal cell carcinoma, Bristol Myers Squibb, Renal cell carcinoma, Nivolumab.
- TrialATTRACTION-2
Shares Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialCheckMate 915
Shares Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialCheckMate 227
Shares Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialCheckMate 358
Shares Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialBOLERO-2
Shares Everolimus and the tag subtype-trials.
- TrialMEDALIST
Shares Bristol Myers Squibb and the tag subtype-trials.